Abstract:The two main pathological hallmarks of Parkinson's disease are loss of dopamine neurons in the substantia nigra pars compacta and proteinaceous amyloid fibrils composed mostly of α-synuclein, called Lewy pathology. Levodopa to enhance dopaminergic transmission remains one of the most effective treatment for alleviating the motor symptoms of Parkinson's disease (Olanow, Mov Disord 34:812-815, 2019). In addition, deep brain stimulation (Bronstein et al., Arch Neurol 68:165, 2011) to modulate basal ganglia circuit activity successfully alleviates some motor symptoms. MRI guided focused ultrasound in the subthalamic nucleus is a promising therapeutic strategy as well (Martinez-Fernandez et al., Lancet Neurol 17:54-63, 2018). However, to date, there exists no treatment that stops the progression of this disease. The findings that α-synuclein can be released from neurons and inherited through interconnected neural networks opened the door for discovering novel treatment strategies to prevent the formation and spread of Lewy pathology with the goal of halting PD in its tracks. This hypothesis is based on discoveries that pathologic aggregates of α-synuclein induce the endogenous α-synuclein protein to adopt a similar pathologic conformation, and is thus self-propagating. Phase I clinical trials are currently ongoing to test treatments such as immunotherapy to prevent the neuron to neuron spread of extracellular aggregates. Although tremendous progress has been made in understanding how Lewy pathology forms and spreads throughout the brain, cell intrinsic factors also play a critical role in the formation of pathologic α-synuclein, such as mechanisms that increase endogenous α-synuclein levels, selective expression profiles in distinct neuron subtypes, mutations and altered function of proteins involved in α-synuclein synthesis and degradation, and oxidative stress. Strategies that prevent the formation of pathologic α-synuclein should consider extracellular release and propagation, as well as neuron intrinsic mechanisms.

The structural features and functions of α-synuclein

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

Protein–protein interactions regulating α-synuclein pathology

Aggregation and phase separation of α-synuclein in Parkinson's disease

Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy

Role of Different Regions of α-Synuclein in the Assembly of Fibrils

Brain region-specific spread of Lewy body pathology in synucleinopathies is governed by α-synuclein conformations.

Structural Insights into α-Synuclein Fibril Polymorphism: Effects of Parkinson's Disease-Related C-Terminal Truncations

Aggregation States of α-Synuclein and Its Involvement in Parkinson’s Disease

Structural Insights of Fe 3+ Induced α-synuclein Fibrillation in Parkinson's Disease

Coupling of the Non-Amyloid-component (NAC) Domain and the KTK(E/Q)GV Repeats Stabilize the Α-Synuclein Fibrils.

Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers

[Alpha-synuclein interacted proteins: the relevance with the pathogenesis of Parkinson's disease].

Initiation and propagation of α-synuclein aggregation in the nervous system

The Roles of Post-translational Modifications on Α-Synuclein in the Pathogenesis of Parkinson’s Diseases

Molecular Insights into the Misfolding and Dimerization Dynamics of the Full-Length Α-Synuclein from Atomistic Discrete Molecular Dynamics Simulations.

Structural packing of the non-amyloid component core domain in α-synuclein plays a role in the stability of the fibrils

Prion-Like Mechanisms in Parkinson’s Disease

Α-Synuclein Aggregation and Transmission in Parkinson’s Disease: a Link to Mitochondria and Lysosome

High-speed Atomic Force Microscopy Reveals Structural Dynamics of Α-Synuclein Monomers and Dimers.

Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease